Engineers Gate Manager LP purchased a new stake in BioScrip Inc (NASDAQ:BIOS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 163,185 shares of the company’s stock, valued at approximately $449,000. Engineers Gate Manager LP owned about 0.13% of BioScrip at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Wells Fargo & Company MN grew its position in shares of BioScrip by 1.0% in the 2nd quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after acquiring an additional 1,100 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of BioScrip by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after acquiring an additional 2,622 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of BioScrip by 9.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after acquiring an additional 8,914 shares during the period. Rhumbline Advisers grew its position in shares of BioScrip by 9.2% in the 2nd quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock valued at $353,000 after acquiring an additional 10,985 shares during the period. Finally, Voya Investment Management LLC grew its position in shares of BioScrip by 41.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after acquiring an additional 14,867 shares during the period. Hedge funds and other institutional investors own 84.69% of the company’s stock.
Shares of BioScrip Inc (NASDAQ:BIOS) opened at $2.71 on Friday. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91. BioScrip Inc has a twelve month low of $0.98 and a twelve month high of $3.39.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. The business’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) earnings per share. analysts expect that BioScrip Inc will post -0.63 earnings per share for the current fiscal year.
BIOS has been the subject of a number of analyst reports. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. SunTrust Banks reaffirmed a “buy” rating and set a $3.00 target price on shares of BioScrip in a report on Friday, November 3rd. Finally, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $3.60.
In other BioScrip news, CEO Daniel E. Greenleaf acquired 15,000 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was purchased at an average price of $2.03 per share, with a total value of $30,450.00. Following the acquisition, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at approximately $62,930. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/17/engineers-gate-manager-lp-purchases-new-position-in-bioscrip-inc-bios.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.